Merck’s (MRK) animal health unit announced that the U.S. FDA approved a label expansion for its once-yearly parasiticide treatment Bravecto Quantum to treat two additional tick species in dogs.

Dr. Aziza Glass is a Doctor of Veterinary Medicine graduate from Cornell University. She was born in Houston, Texas, and nurtured her love of animals by watching television documentaries and ...

SUMMIT, N.J., May 20, 2014 /PRNewswire/ -- Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced the U.S. Food and Drug Administration's approval of ...

Merck's animal health unit got approval for a drug to treat and control certain ticks in dogs from the Food and Drug Administration. Merck said Wednesday its Bravecto Quantum is now approved to treat ...

The US Food and Drug Administration has approved Merck Animal Health's Bravecto (fluralaner) chewable tablets for dogs (112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg). Bravecto is the first and only ...

“Approval of BRAVECTO Spot-On builds on the strong foundation and body of scientific evidence that we have established with our chewable tablet for dogs, the oral flea and tick product available today ...

First Chewable Tablet for Dogs Effective for 12 Weeks* Against Fleas and Ticks SUMMIT, NJ, May 20, 2014 – Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today ...